Design, synthesis and biological evaluation of 2-(substituted phenyl)thiazolidine-4-carboxylic acid derivatives as novel tyrosinase inhibitors. 2012

Young Mi Ha, and Yun Jung Park, and Ji Yeon Lee, and Daeui Park, and Yeon Ja Choi, and Eun Kyeong Lee, and Ji Min Kim, and Jin-Ah Kim, and Ji Young Park, and Hye Jin Lee, and Hyung Ryong Moon, and Hae Young Chung
Molecular Inflammation Research Center for Aging Intervention, College of Pharmacy, Pusan National University, Kumjeong-Gu, Busan 609-735, Republic of Korea.

Herein we describe the design, synthesis and biological activities of 2-(substituted phenyl)thiazolidine-4-carboxylic acid derivatives as novel tyrosinase inhibitors. The target compounds 2a-2j were designed and synthesized from the structural characteristics of N-phenylthiourea, tyrosinase inhibitor and tyrosine, and l-DOPA, the natural substrates of tyrosinase. Among them, (2R/S,4R)-2-(2,4-dimethoxyphenyl)thiazolidine-4-carboxylic acid (2g) caused the greatest inhibition 66.47% at 20 μM of l-DOPA oxidase activity of mushroom tyrosinase. Kinetic analysis of tyrosinase inhibition revealed that 2g is a competitive inhibitor. We predicted the tertiary structure of tyrosinase, and simulated the docking of mushroom tyrosinase with 2g. These results suggest that the binding affinity of 2g with tyrosinase is high. Also, 2g effectively inhibited tyrosinase activity and reduced melanin levels in B16 cells treated with α-MSH. These data strongly suggest that 2g can suppress the production of melanin via the inhibition of tyrosinase activity.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D008543 Melanins Insoluble polymers of TYROSINE derivatives found in and causing darkness in skin (SKIN PIGMENTATION), hair, and feathers providing protection against SUNBURN induced by SUNLIGHT. CAROTENES contribute yellow and red coloration. Allomelanins,Melanin,Phaeomelanins
D008546 Melanoma, Experimental Experimentally induced tumor that produces MELANIN in animals to provide a model for studying human MELANOMA. B16 Melanoma,Melanoma, B16,Melanoma, Cloudman S91,Melanoma, Harding-Passey,Experimental Melanoma,Experimental Melanomas,Harding Passey Melanoma,Melanomas, Experimental,B16 Melanomas,Cloudman S91 Melanoma,Harding-Passey Melanoma,Melanoma, Harding Passey,Melanomas, B16,S91 Melanoma, Cloudman
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D010670 Phenylthiourea Phenylthiourea is a THIOUREA derivative containing a phenyl ring. Depending on their genetic makeup, humans can find it either bitter-tasting or tasteless. Phenylthiocarbamide
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D000363 Agaricales An extensive order of basidiomycetous fungi whose fruiting bodies are commonly called mushrooms. Agaricaceae,Mushrooms,Agaricale,Mushroom
D000521 alpha-MSH A 13-amino acid peptide derived from proteolytic cleavage of ADRENOCORTICOTROPIC HORMONE, the N-terminal segment of ACTH. ACTH (1-13) is amidated at the C-terminal to form ACTH (1-13)NH2 which in turn is acetylated to form alpha-MSH in the secretory granules. Alpha-MSH stimulates the synthesis and distribution of MELANIN in MELANOCYTES in mammals and MELANOPHORES in lower vertebrates. MSH, alpha,alpha Intermedin,alpha-Melanocyte-Stimulating Hormone,(Des-Acetyl)-alpha-MSH,(Desacetyl)alpha-MSH,ACTH (1-13),ACTH (1-13)NH2,ACTH(1-13),Acetylated ACTH (1-13)NH2,Adrenocorticotropin (1-13)NH2,DE-alpha-MSH,Des-Acetyl MSH,Desacetyl alpha-MSH,Desacetyl alpha-Melanocyte-Stimulating Hormone,MSH, (Desacetyl)alpha-,alpha-Melanotropin,Desacetyl alpha MSH,Desacetyl alpha Melanocyte Stimulating Hormone,Hormone, Desacetyl alpha-Melanocyte-Stimulating,Hormone, alpha-Melanocyte-Stimulating,Intermedin, alpha,MSH, Des-Acetyl,alpha MSH,alpha Melanocyte Stimulating Hormone,alpha Melanotropin,alpha-MSH, Desacetyl,alpha-Melanocyte-Stimulating Hormone, Desacetyl

Related Publications

Young Mi Ha, and Yun Jung Park, and Ji Yeon Lee, and Daeui Park, and Yeon Ja Choi, and Eun Kyeong Lee, and Ji Min Kim, and Jin-Ah Kim, and Ji Young Park, and Hye Jin Lee, and Hyung Ryong Moon, and Hae Young Chung
April 2011, Bioorganic & medicinal chemistry,
Young Mi Ha, and Yun Jung Park, and Ji Yeon Lee, and Daeui Park, and Yeon Ja Choi, and Eun Kyeong Lee, and Ji Min Kim, and Jin-Ah Kim, and Ji Young Park, and Hye Jin Lee, and Hyung Ryong Moon, and Hae Young Chung
February 2010, European journal of medicinal chemistry,
Young Mi Ha, and Yun Jung Park, and Ji Yeon Lee, and Daeui Park, and Yeon Ja Choi, and Eun Kyeong Lee, and Ji Min Kim, and Jin-Ah Kim, and Ji Young Park, and Hye Jin Lee, and Hyung Ryong Moon, and Hae Young Chung
November 2019, European journal of medicinal chemistry,
Young Mi Ha, and Yun Jung Park, and Ji Yeon Lee, and Daeui Park, and Yeon Ja Choi, and Eun Kyeong Lee, and Ji Min Kim, and Jin-Ah Kim, and Ji Young Park, and Hye Jin Lee, and Hyung Ryong Moon, and Hae Young Chung
September 2021, BMC chemistry,
Young Mi Ha, and Yun Jung Park, and Ji Yeon Lee, and Daeui Park, and Yeon Ja Choi, and Eun Kyeong Lee, and Ji Min Kim, and Jin-Ah Kim, and Ji Young Park, and Hye Jin Lee, and Hyung Ryong Moon, and Hae Young Chung
January 2020, Bioorganic chemistry,
Young Mi Ha, and Yun Jung Park, and Ji Yeon Lee, and Daeui Park, and Yeon Ja Choi, and Eun Kyeong Lee, and Ji Min Kim, and Jin-Ah Kim, and Ji Young Park, and Hye Jin Lee, and Hyung Ryong Moon, and Hae Young Chung
June 2023, Pharmaceuticals (Basel, Switzerland),
Young Mi Ha, and Yun Jung Park, and Ji Yeon Lee, and Daeui Park, and Yeon Ja Choi, and Eun Kyeong Lee, and Ji Min Kim, and Jin-Ah Kim, and Ji Young Park, and Hye Jin Lee, and Hyung Ryong Moon, and Hae Young Chung
January 2022, PloS one,
Young Mi Ha, and Yun Jung Park, and Ji Yeon Lee, and Daeui Park, and Yeon Ja Choi, and Eun Kyeong Lee, and Ji Min Kim, and Jin-Ah Kim, and Ji Young Park, and Hye Jin Lee, and Hyung Ryong Moon, and Hae Young Chung
January 2005, Bioorganic & medicinal chemistry,
Young Mi Ha, and Yun Jung Park, and Ji Yeon Lee, and Daeui Park, and Yeon Ja Choi, and Eun Kyeong Lee, and Ji Min Kim, and Jin-Ah Kim, and Ji Young Park, and Hye Jin Lee, and Hyung Ryong Moon, and Hae Young Chung
February 2020, European journal of medicinal chemistry,
Young Mi Ha, and Yun Jung Park, and Ji Yeon Lee, and Daeui Park, and Yeon Ja Choi, and Eun Kyeong Lee, and Ji Min Kim, and Jin-Ah Kim, and Ji Young Park, and Hye Jin Lee, and Hyung Ryong Moon, and Hae Young Chung
March 2016, Molecules (Basel, Switzerland),
Copied contents to your clipboard!